Skip to content
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Loading stock detail

Preparing the latest stock view…

We're pulling the screening verdict, quote snapshot, and company context now.

Is Dr. Reddy's Laboratories Limited Shariah Compliant? | BarakFi | BarakFi
NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%NIFTY 5023,842.75+0.54%SENSEX78,553.20+0.54%NIFTY BANK51,236.80-0.17%NIFTY IT33,156.40+0.75%NIFTY PHARMA19,872.35+0.28%NIFTY AUTO23,145.90-0.48%NIFTY FMCG56,234.15+0.32%INDIA VIX13.42-2.75%
BarakFi
ScreenerExploreToolsWatchlist
Log inGet started
Home›Screener›DRREDDY
DRREDDY logo
DRREDDYNSE

Dr. Reddy's Laboratories Limited

Pharmaceuticals · Large Cap · India
₹1,307.2
▼ ₹24 (-1.80%) today
Day Range: ₹1,305.1 – ₹1,329.6
Volume: 20.0 L · as of 24 May 2026, 4:43 am
Shariah Status
Shariah Compliant
Report Credit
Opening this stock page uses 1 of your 50 monthly report credits.
Last screened 29 May 2026, 7:33 pm IST.
Methodology
AAOIFI aligned · 2026.04.2
See Full Breakdown
Shariah Compliant
Compliance
Market Data
About
Similar Stocks
Add to Watchlist
Share
Shariah Compliance Breakdown
Debt Ratio
Interest-bearing debt compared to methodology denominator (AAOIFI: total assets). Must stay below 30%.
Disclaimer:The information on this page is for educational purposes only and does not constitute a religious ruling (fatwa) or financial advice. Shariah compliance status is derived from publicly available financial data and BarakFi's methodology mapping. Individual scholars may reach different conclusions. Always consult a qualified Islamic finance scholar and a licensed financial advisor before making investment decisions.
BarakFi
Shariah-compliant stock research for Indian equities. Educational only.
Product
ScreenerWatchlistCompare
Learn
MethodologyAbout
Legal
PrivacyDisclaimer
© 2026 BarakFi · Educational screening · Not a religious ruling or financial adviceMade in India
Threshold: 30%
10.8%
Pass
Interest Income
Interest and treasury-based income as a share of business income. Must stay below 5%.
Threshold: 5%
0.0%
Pass
Non-permissible Income
Non-halal income compared to total business income. Must stay below 5%.
Threshold: 5%
Not detected
Pass
Accounts Receivable
Receivables compared to methodology denominator (AAOIFI: total assets). Must stay below 49%.
Threshold: 49%
17.4%
Pass
Business Activity
Core business lines should avoid prohibited sectors and interest-driven revenue dependence.
Allowed
Pass
Cash & Interest-bearing Assets
Cash, equivalents, and interest-bearing balances compared to total assets. Must stay below 30%.
Threshold: 30%
9.2%
Pass
Why Shariah Compliant
Dr. Reddy's Laboratories Limited currently screens as Shariah compliant on BarakFi. All required checks pass with current data.
Market Data
Current Price
₹1,307.2
Day Range
₹1,305.1 – ₹1,329.6
52-Week Range
₹1,148.4 – ₹1,379.7
Volume
20.0 L
Market Cap
₹1.09 L Cr
P/E Ratio
18.0×
About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 24,832 full-time employees. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

BarakFi combines that company context with filing-driven screening ratios, market-cap evidence, and live quote snapshots so you can review the stock through a Shariah-screening lens without losing the underlying business picture.

Index and universe context: Nifty 100 • Nifty 50 • Nifty 500.

PharmaceuticalsLarge CapIndiaNSENifty 100Nifty 50Nifty 500
Other Stocks in Pharmaceuticals
No nearby sector peers available yet.
Key Compliance Ratios
Debt Ratio10.8%
Interest Income0.0%
Non-permissible IncomeNot detected
Receivables Ratio17.4%
Overall StatusCompliant
Stock Information
TickerDRREDDY
ExchangeNSE
SectorPharmaceuticals
CountryIndia
Market Cap₹1.09 L Cr
36M Avg MCap₹1.01 L Cr
Cap SizeLarge Cap
About this Screening
This page uses an AAOIFI-aligned methodology version 2026.04.2, checking debt, interest income, non-permissible income, receivables, and balance-sheet context from the current filings dataset.

This is educational only — not a religious ruling or financial advice. Read the full methodology for threshold context and update cadence.

Read full methodology →
Track this stock
Add DRREDDY to your watchlist so you can revisit its status after the next fundamentals sync.
Open Watchlist